(Reuters) – The U.S. Food and Drug Administration on Friday warned patients and health care professionals not to use compounded drugs, including versions of popular weight-loss treatments, made by California-based Fullerton Wellness.
Fullerton Wellness is a facility that makes compounded versions of Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide injections, among others.
(Reporting by Sneha S K in Bengaluru; editing by Alan Barona)
